Kymera Therapeutics
KYMR
52 hedge funds and large institutions have $543M invested in Kymera Therapeutics in 2020 Q3 according to their latest regulatory filings, with 52 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
37.87% more ownership
Funds ownership: 0% → 37.87% (+38%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$83.4M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$80.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$69M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$59.8M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$53.9M |
Top Sellers
KYMR Hedge Fund Activity: Q3 2020 in Review
52 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q3 2020, worth a combined $543M.
Buyers outnumbered sellers: 52 funds opened new KYMR positions and 0 closed out — a net gain of 52 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Redmile Group, opening a new position worth an estimated $83.4M.
- 52 institutional investors held Kymera Therapeutics (KYMR) as of Q3 2020, up from 0 in Q2 2020.
- Funds reported $543M of Kymera Therapeutics stock for Q3 2020.
- 52 funds opened new Kymera Therapeutics positions in Q3 2020 and 0 closed out, a net change of +52 holders.
- The largest Kymera Therapeutics buyer in Q3 2020 was Redmile Group, an estimated $83.4M added.
Based on aggregated 13F filings for Q3 2020.